Biogen share price today

(BIIB)

Biogen share price is $146.47 & ₹12,446.43 as on 21 Dec 2024, 2.30 'hrs' IST

$146.47

▲

-0.92

(-0.62%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Biogen share price in Dollar and Rupees. Guide to invest in Biogen from India. Also see the sentimental analysis on Indian investors investing in Biogen. Get details on the Indian mutual funds that are investing in Biogen. Get Analyst recommendations and forecasts along with all the Biogen's financials.

Biogen share price movements

Today's Low: $145.46
Today's High: $147.81
$146.47
0.69%
Downside
Day's Volatility :1.59%
Upside
0.9%
52 Weeks Low: $145.07
52 Weeks High: $268.30
$146.47
0.96%
Downside
52 Weeks Volatility :45.93%
Upside
45.41%

Biogen Returns

Period	Biogen Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-25.2%	-11.1%	0.0%
6 Months	-35.36%	-6.0%	0.0%
1 Year	-43.82%	2.7%	0.0%
3 Years	-37.78%	0.6%	-19.7%

Biogen Key Statistics

in dollars & INR

Previous Close	$147.39
Open	$145.64
Today's High	$147.805
Today's Low	$145.46
Market Capitalization	$21.5B
Today's Volume	$5.5M
52 Week High	$268.295
52 Week Low	$145.0709
Revenue TTM	$9.6B
EBITDA	$2.9B
Earnings Per Share (EPS)	$10.99
PE Ratio	13.33
Profit Margin	16.81%
Quarterly Earnings Growth YOY	-0.02%
Return On Equity TTM	10.47%

How to invest in Biogen from India?

It is very easy for Indian residents to invest directly in Biogen from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biogen stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biogen or BIIB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biogen or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biogen shares which would translate to 0.006 fractional shares of Biogen as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Biogen, in just a few clicks!

Returns in Biogen for Indian investors in Rupees

Investment Value

₹1,00,000

Biogen investment value today

Current value as on today

₹1,46,013

Returns

₹46,013

(+46.01%)

Returns from Biogen Stock

₹43,817 (false-43.82%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Biogen

-18.0%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Investment in Biogen from India has reduced in the last 30 days as on Dec 22, 2024. -18.0% less purchase transactions for Biogen in the last 30 days versus the previous period.

-5%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Biogen on INDmoney from India has reduced in the last 30 days as on Dec 22, 2024. -5% less investors are searching Biogen in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Biogen

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	1252	-8.63	0.04%
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	26352	-3393.87	1.07%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	1887	0.00	0.17%

Global Institutional Holdings in Biogen

Vanguard Group Inc
11.45%
PRIMECAP Management Company
11.20%
BlackRock Inc
9.98%
State Street Corp
5.04%
Wellington Management Company LLP
3.52%
JPMorgan Chase & Co
3.50%

Analyst Recommendation on Biogen

Buy

71%Buy

28%Hold

0%Sell

Based on 42 Wall street analysts offering stock ratings for Biogen(by analysts ranked 0 to 5 stars)

Based on 42 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biogen

What analysts predicted

Upside of 65.79%

Current:

$146.47

Target:

$242.83

Insights on Biogen

Price Movement
In the last 3 months, BIIB stock has moved down by -26.5%
Increasing Revenue
Revenue is up for the last 3 quarters, 2.20B → 2.46B (in $), with an average increase of 5.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 583.6M → 388.5M (in $), with an average decrease of 33.4% per quarter
BIIB vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 34.2% return, outperforming this stock by 76.5%
BIIB vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 189.9% return, outperforming this stock by 227.5%
Price to Sales
ForBIIB every $1 of sales, investors are willing to pay $2.2, whereas for Eli Lilly And Company, the investors are paying $16.9 for every $1 of sales.

Biogen Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$13.5B	↑ 9.61%
Net Income	$4.4B	↑ 74.5%
Net Profit Margin	32.93%	↑ 12.24%

	FY19	Y/Y Change
Revenue	$14.4B	↑ 6.88%
Net Income	$5.9B	↑ 32.9%
Net Profit Margin	40.96%	↑ 8.03%

	FY20	Y/Y Change
Revenue	$13.4B	↓ 6.49%
Net Income	$4.0B	↓ 32.06%
Net Profit Margin	29.76%	↓ 11.2%

	FY21	Y/Y Change
Revenue	$11.0B	↓ 18.32%
Net Income	$1.6B	↓ 61.1%
Net Profit Margin	14.17%	↓ 15.59%

	FY22	Y/Y Change
Revenue	$10.2B	↓ 7.36%
Net Income	$3.0B	↑ 95.8%
Net Profit Margin	29.95%	↑ 15.78%

	FY23	Y/Y Change
Revenue	$9.8B	↓ 3.32%
Net Income	$1.2B	↓ 61.89%
Net Profit Margin	11.81%	↓ 18.14%

	Q2 FY23	Q/Q Change
Revenue	$2.5B	↓ 0.28%
Net Income	$591.6M	↑ 52.51%
Net Profit Margin	24.09%	↑ 8.34%

	Q3 FY23	Q/Q Change
Revenue	$2.5B	↑ 3.03%
Net Income	$-68.1M	↓ 111.51%
Net Profit Margin	-2.69%	↓ 26.78%

	Q4 FY23	Q/Q Change
Revenue	$2.4B	↓ 5.69%
Net Income	$249.7M	↓ 466.67%
Net Profit Margin	10.46%	↑ 13.15%

	Q1 FY24	Q/Q Change
Revenue	$2.2B	↓ 7.79%
Net Income	$393.4M	↑ 57.55%
Net Profit Margin	17.88%	↑ 7.42%

	Q2 FY24	Q/Q Change
Revenue	$2.4B	↑ 6.94%
Net Income	$583.6M	↑ 48.35%
Net Profit Margin	24.8%	↑ 6.92%

	Q3 FY24	Q/Q Change
Revenue	$2.5B	↑ 4.79%
Net Income	$388.5M	↓ 33.43%
Net Profit Margin	15.76%	↓ 9.04%

	FY18	Y/Y Change
Profit	$11.6B	↑ 9.33%

	FY19	Y/Y Change
Profit	$12.4B	↑ 6.75%

	FY20	Y/Y Change
Profit	$11.6B	↓ 6.3%

	FY21	Y/Y Change
Profit	$8.9B	↓ 23.78%

	FY22	Y/Y Change
Profit	$7.9B	↓ 11.01%

	FY23	Y/Y Change
Profit	$7.3B	↓ 7.51%

	Q2 FY23	Q/Q Change
Profit	$1.9B	↑ 3.51%

	Q3 FY23	Q/Q Change
Profit	$1.9B	↑ 0.4%

	Q4 FY23	Q/Q Change
Profit	$1.8B	↓ 5.49%

	Q1 FY24	Q/Q Change
Profit	$1.5B	↓ 14.56%

	Q2 FY24	Q/Q Change
Profit	$1.6B	↑ 9.12%

	Q3 FY24	Q/Q Change
Profit	$1.8B	↑ 10.85%

	FY18	Y/Y Change
Operating Cash Flow	$6.2B	↑ 35.96%
Investing Cash Flow	$-2.0B	↓ 30.94%
Financing Cash Flow	$-4.5B	↑ 87.9%

	FY19	Y/Y Change
Operating Cash Flow	$7.1B	↑ 14.4%
Investing Cash Flow	$470.5M	↓ 122.99%
Financing Cash Flow	$-5.9B	↑ 31.05%

	FY20	Y/Y Change
Operating Cash Flow	$4.2B	↓ 40.25%
Investing Cash Flow	$-608.6M	↓ 229.35%
Financing Cash Flow	$-5.3B	↓ 10.03%

	FY21	Y/Y Change
Operating Cash Flow	$3.6B	↓ 13.95%
Investing Cash Flow	$-563.7M	↓ 7.38%
Financing Cash Flow	$-2.1B	↓ 60.43%

	FY22	Y/Y Change
Operating Cash Flow	$1.4B	↓ 61.97%
Investing Cash Flow	$1.6B	↓ 379.69%
Financing Cash Flow	$-1.8B	↓ 15.65%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$487.0M	↑ 6.96%
Investing Cash Flow	$-753.5M	↓ 20.93%
Financing Cash Flow	$-9.8M	↓ 77.42%

Biogen Technicals Summary

Sell

Neutral

Buy

Biogen is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Biogen Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biogen Inc.	-7.24%	-35.36%	-43.82%	-37.78%	-51.83%
Eli Lilly And Company	2.64%	-13.75%	34.54%	181.13%	485.58%
Johnson & Johnson	-6.9%	-3.12%	-7.47%	-14.13%	-1.0%
Merck & Co. Inc.	-1.14%	-26.26%	-8.9%	29.47%	7.23%
Novo Nordisk A/s	-19.09%	-40.26%	-17.22%	56.78%	193.26%
Abbvie Inc	-0.77%	1.64%	13.56%	31.93%	95.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biogen Inc.	13.33	13.33	6.24	16.43	0.1	0.05	NA	112.28
Eli Lilly And Company	81.9	81.9	0.71	13.15	0.65	0.14	0.01	15.83
Johnson & Johnson	23.73	23.73	0.86	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.82	20.82	0.07	7.74	0.28	0.11	0.03	17.58
Novo Nordisk A/s	34.71	34.71	1.54	22.85	0.89	0.21	0.01	27.07
Abbvie Inc	59.97	59.97	0.41	10.94	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biogen Inc.	Buy	$21.5B	-51.83%	13.33	16.81%
Eli Lilly And Company	Buy	$681.3B	485.58%	81.9	20.48%
Johnson & Johnson	Buy	$345.7B	-1.0%	23.73	16.74%
Merck & Co. Inc.	Buy	$251.7B	7.23%	20.82	19.23%
Novo Nordisk A/s	Buy	$482.1B	193.26%	34.71	35.01%
Abbvie Inc	Buy	$303.1B	95.41%	59.97	9.22%

About Biogen

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Organization	Biogen
Employees	7570
CEO	Mr. Christopher A. Viehbacher
Industry	Health Technology

Management People of Biogen

Name	Title
Mr. Christopher A. Viehbacher	President, CEO & Director
Mr. Michael R. McDonnell CPA	Executive VP & CFO
Ms. Nicole Murphy	Head of Pharmaceutical Operations & Technology
Ms. Susan H. Alexander Esq.	Executive VP & Chief Legal Officer
Mr. Rachid Izzar	Head of Global Product Strategy & Commercialization
Ms. Robin C. Kramer	Senior VP & Chief Accounting Officer
Dr. Stephen Amato	Head of Investor Relations
Ms. Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs
Mr. Adam Keeney Ph.D.	Executive VP & Head of Corporate Development
Dr. Ginger Gregory Ph.D.	Executive VP & Chief Human Resources Officer

Important FAQs about investing in Biogen from India :

What is Biogen share price today?

Biogen share price today stands at $146.47, Open: $145.64 ; Previous Close: $147.39 ; High: $147.81 ; Low: $145.46 ; 52 Week High: $268.30 ; 52 Week Low: $145.07. The stock opens at $145.64, after a previous close of $147.39. The stock reached a daily high of $147.81 and a low of $145.46, with a 52-week high of $268.30 and a 52-week low of $145.07.

Can Indians buy Biogen shares?

Yes, Indians can invest in the Biogen (BIIB) from India.

With INDmoney, you can buy Biogen at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biogen at zero transaction cost.

How can I buy Biogen shares from India?

It is very easy to buy Biogen from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biogen be purchased?

Yes, you can buy fractional shares of Biogen with INDmoney app.

What are the documents required to start investing in Biogen stocks?

To start investing in Biogen, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.